The insurance payment of 'Seretide' for the treatment has asthma and COPD (chronic obstructive pulmonary disease), was enlarged

Published: 2014-02-14 16:50:40

Updated: 2014-02-14 16:50:40

GlaxoSmithKline announced that the insurance payment of 'Seretide' which was approved for the treatment has asthma and COPD (chronic obstructive pulmonary disease), was enlarged starting from January 2014.

Ministry of Health and Welfare expanded the insurance payment of 'Seretide' from previous criteria 'moderate persistent asthma' to 'partly controlled asthma'. Therefore, Seretide can be pres...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.